Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pomalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 18/20 | 0.97 |
| ▸ | DDB1 known ✓ | Q16531 | 17/20 | 0.97 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.97 |
| ▸ | TNF | P01375 | 2/20 | 0.97 |
| ▸ | IL1B | P01584 | 2/20 | 0.97 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pomalidomide SCHEMBL20525238 | 1.00 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL20525246 | 1.00 | CRBN (0.97) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL19250920 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL563317 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL29382107 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930065 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL369172 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL931134 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930059 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| Pomalidomide SCHEMBL15930061 | 0.99 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065423-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | claimed |
| US-11866417-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-01-09 | — | — | US | claimed |
| US-20210230136-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2021-07-29 | — | — | US | claimed |
| US-10919873-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2021-02-16 | — | — | US | claimed |
| US-20210024488-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2021-01-28 | — | — | US | claimed |
| US-10829472-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2020-11-10 | — | — | US | claimed |
| US-20200262810-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-08-20 | — | — | US | claimed |
| US-20200140408-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-07 | — | — | US | claimed |
| US-10590103-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-YL)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2020-03-17 | — | — | US | claimed |
| US-20190092748-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-03-28 | — | — | US | claimed |
| US-20190092747-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-03-28 | — | — | US | claimed |
| US-10093649-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | claimed |
| US-10093648-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | claimed |
| US-12065423-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-12065423-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-12065423-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| US-10093648-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093648-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093649-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| US-10093649-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | CELGENE CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829472-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-10590103-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-YL)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-10093649-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-20210024488-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-20210230136-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-20200140408-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-20190092747-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-10919873-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-20200262810-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE MONOHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-11866417-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-10093648-B1 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
| US-12065423-B2 | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | QDPR, UACA, DCTN3 | CRBN 3544/4885DDB1 1207/4885IKZF3 2946/4885 |
| US-20190092748-A1 | CRYSTALLINE 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE HEMIHYDRATE, COMPOSITIONS AND METHODS OF USE THEREOF | QDPR, HTR3D, IAPP | CRBN 3178/4885DDB1 1657/4885IKZF3 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.